S&CO Inc. Increases Position in Humana Inc. (NYSE:HUM)

S&CO Inc. lifted its position in Humana Inc. (NYSE:HUM) by 16.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,760 shares of the insurance provider’s stock after purchasing an additional 4,762 shares during the period. S&CO Inc.’s holdings in Humana were worth $10,693,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Thrivent Financial for Lutherans lifted its position in Humana by 55.6% during the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after purchasing an additional 214,535 shares during the last quarter. AM Squared Ltd lifted its holdings in shares of Humana by 200.0% in the 3rd quarter. AM Squared Ltd now owns 300 shares of the insurance provider’s stock worth $95,000 after acquiring an additional 200 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in Humana by 12.4% in the 3rd quarter. Mutual of America Capital Management LLC now owns 21,717 shares of the insurance provider’s stock worth $6,879,000 after buying an additional 2,395 shares during the period. Kinsale Capital Group Inc. increased its stake in Humana by 21.2% in the 3rd quarter. Kinsale Capital Group Inc. now owns 11,777 shares of the insurance provider’s stock worth $3,730,000 after buying an additional 2,062 shares during the period. Finally, Natixis Advisors LLC increased its stake in Humana by 1.1% in the 3rd quarter. Natixis Advisors LLC now owns 96,375 shares of the insurance provider’s stock worth $30,526,000 after buying an additional 1,023 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Down 2.6 %

HUM opened at $275.67 on Friday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $527.18. The business has a 50-day moving average of $281.36 and a 200-day moving average of $331.81. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $33.19 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52.

Humana (NYSE:HUM) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities research analysts forecast that Humana Inc. will post 15.86 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.28%. Humana’s payout ratio is 31.36%.

Wall Street Analyst Weigh In

A number of research analysts have commented on HUM shares. KeyCorp began coverage on shares of Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. JPMorgan Chase & Co. lifted their target price on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Truist Financial decreased their price objective on shares of Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research note on Friday, October 11th. Leerink Partnrs lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Sanford C. Bernstein raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a report on Tuesday, October 8th. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.